Sivik Global Healthcare’s Charles River Laboratories CRL Stock Holding History

Sivik Global Healthcare’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,000	Closed	-$6.77M	–	43
2024 Q1	$6.77M	Buy	+25,000	New	+$5.97M	1.59%	15
2023 Q3	–	Sell	-13,000	Closed	-$2.73M	–	39
2023 Q2	$2.73M	Buy	+13,000	New	+$2.59M	0.64%	36
2022 Q3	–	Sell	-15,000	Closed	-$3.21M	–	42
2022 Q2	$3.21M	Sell	15,000 -5,000	-25%	-$1.22M	1.82%	30
2022 Q1	$5.68M	Buy	20,000 +5,000	+33%	+$1.54M	2.34%	18
2021 Q4	$5.65M	Sell	15,000 -5,000	-25%	-$1.94M	2.42%	19
2021 Q3	$8.25M	Sell	20,000 -5,000	-20%	-$2.08M	1.97%	18
2021 Q2	$9.25M	Buy	25,000 +2,500	+11%	+$835K	1.81%	11
2021 Q1	$6.52M	Buy	22,500 +2,500	+13%	+$695K	2.38%	23
2020 Q4	$5M	Sell	20,000 -5,000	-20%	-$1.19M	2.04%	29
2020 Q3	$5.66M	Buy	+25,000	New	+$5.19M	2.43%	23
2020 Q2	–	Sell	-15,000	Closed	-$4.04M	–	54
2020 Q1	$4.04M	Buy	+15,000	New	+$2.25M	1.59%	30

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Sivik Global Healthcare's CRL Position: Q2 2024 in Review

Sivik Global Healthcare sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 25,000 shares — an estimated $6.77M sold.

Sivik Global Healthcare first reported a position in CRL in Q1 2020 and held it in 11 quarters. The position peaked at $9.25M in Q2 2021. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Sivik Global Healthcare reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
Sivik Global Healthcare sold 25,000 Charles River Laboratories shares in Q2 2024, an estimated $6.77M.
Sivik Global Healthcare first reported a position in Charles River Laboratories in Q1 2020 and held it in 11 quarters.
Sivik Global Healthcare's Charles River Laboratories position peaked at $9.25M in Q2 2021.
665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Sivik Global Healthcare's 13F filing for Q2 2024, filed 29 Jul 2024.